Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.7% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) fell 5.7% during mid-day trading on Tuesday . The stock traded as low as $35.01 and last traded at $34.99. 10,073 shares changed hands during trading, a decline of 83% from the average session volume of 60,093 shares. The stock had previously closed at $37.12.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. UBS Group upped their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Leerink Partners upped their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Finally, Guggenheim upped their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Stock Down 6.1%

The company’s fifty day moving average price is $37.75 and its 200 day moving average price is $29.57.

Nanobiotix (NASDAQ:NBTX) last announced its earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million for the quarter. As a group, sell-side analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.19 EPS for the current year.

Institutional Trading of Nanobiotix

Several institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC purchased a new stake in shares of Nanobiotix in the fourth quarter valued at about $390,000. Royal Bank of Canada raised its holdings in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Nanobiotix in the fourth quarter valued at about $220,000. Finally, Optiver Holding B.V. purchased a new position in shares of Nanobiotix in the 3rd quarter worth about $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.